Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Peritoneal Metastasis

Bradley Hall, James Padussis, Jason M Foster

Research output: Contribution to journalReview article

3 Citations (Scopus)

Abstract

Historically, patients with peritoneal carcinomatosis secondary to colorectal cancer have a poor overall prognosis. Recent data support the use of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS + HIPEC) to specifically address the peritoneal disease. Retrospective studies on CRS + HIPEC have been promising, showing significant improvements in OS compared with systemic chemotherapy alone. However, CRS + HIPEC carries morbidity similar to other advance oncology procedures such as liver resection and pancreatoduonectomy. It is hoped that ongoing clinical trials will clarify its role in the treatment of patients with peritoneal metastatic colorectal cancer.

Original languageEnglish (US)
Pages (from-to)671-682
Number of pages12
JournalSurgical Clinics of North America
Volume97
Issue number3
DOIs
StatePublished - Jun 2017

Fingerprint

Colorectal Neoplasms
Peritoneal Diseases
Neoplasm Metastasis
Drug Therapy
Retrospective Studies
Clinical Trials
Morbidity
Carcinoma
Liver
Therapeutics

Keywords

  • CC score
  • Cytoreductive surgery (CRS)
  • Hyperthermic intraperitoneal chemotherapy (HIPEC)
  • Intraperitoneal chemotherapy (IP)
  • Peritoneal carcinoma index (PCI)
  • Peritoneal metastasis (PM)
  • R score

ASJC Scopus subject areas

  • Surgery
  • Medicine(all)

Cite this

Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Peritoneal Metastasis. / Hall, Bradley; Padussis, James; Foster, Jason M.

In: Surgical Clinics of North America, Vol. 97, No. 3, 06.2017, p. 671-682.

Research output: Contribution to journalReview article

@article{3a33b7a041064cf69ce965f8fd67f08b,
title = "Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Peritoneal Metastasis",
abstract = "Historically, patients with peritoneal carcinomatosis secondary to colorectal cancer have a poor overall prognosis. Recent data support the use of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS + HIPEC) to specifically address the peritoneal disease. Retrospective studies on CRS + HIPEC have been promising, showing significant improvements in OS compared with systemic chemotherapy alone. However, CRS + HIPEC carries morbidity similar to other advance oncology procedures such as liver resection and pancreatoduonectomy. It is hoped that ongoing clinical trials will clarify its role in the treatment of patients with peritoneal metastatic colorectal cancer.",
keywords = "CC score, Cytoreductive surgery (CRS), Hyperthermic intraperitoneal chemotherapy (HIPEC), Intraperitoneal chemotherapy (IP), Peritoneal carcinoma index (PCI), Peritoneal metastasis (PM), R score",
author = "Bradley Hall and James Padussis and Foster, {Jason M}",
year = "2017",
month = "6",
doi = "10.1016/j.suc.2017.01.013",
language = "English (US)",
volume = "97",
pages = "671--682",
journal = "Surgical Clinics of North America",
issn = "0039-6109",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy in the Management of Colorectal Peritoneal Metastasis

AU - Hall, Bradley

AU - Padussis, James

AU - Foster, Jason M

PY - 2017/6

Y1 - 2017/6

N2 - Historically, patients with peritoneal carcinomatosis secondary to colorectal cancer have a poor overall prognosis. Recent data support the use of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS + HIPEC) to specifically address the peritoneal disease. Retrospective studies on CRS + HIPEC have been promising, showing significant improvements in OS compared with systemic chemotherapy alone. However, CRS + HIPEC carries morbidity similar to other advance oncology procedures such as liver resection and pancreatoduonectomy. It is hoped that ongoing clinical trials will clarify its role in the treatment of patients with peritoneal metastatic colorectal cancer.

AB - Historically, patients with peritoneal carcinomatosis secondary to colorectal cancer have a poor overall prognosis. Recent data support the use of cytoreductive surgery and heated intraperitoneal chemotherapy (CRS + HIPEC) to specifically address the peritoneal disease. Retrospective studies on CRS + HIPEC have been promising, showing significant improvements in OS compared with systemic chemotherapy alone. However, CRS + HIPEC carries morbidity similar to other advance oncology procedures such as liver resection and pancreatoduonectomy. It is hoped that ongoing clinical trials will clarify its role in the treatment of patients with peritoneal metastatic colorectal cancer.

KW - CC score

KW - Cytoreductive surgery (CRS)

KW - Hyperthermic intraperitoneal chemotherapy (HIPEC)

KW - Intraperitoneal chemotherapy (IP)

KW - Peritoneal carcinoma index (PCI)

KW - Peritoneal metastasis (PM)

KW - R score

UR - http://www.scopus.com/inward/record.url?scp=85019255522&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85019255522&partnerID=8YFLogxK

U2 - 10.1016/j.suc.2017.01.013

DO - 10.1016/j.suc.2017.01.013

M3 - Review article

C2 - 28501254

AN - SCOPUS:85019255522

VL - 97

SP - 671

EP - 682

JO - Surgical Clinics of North America

JF - Surgical Clinics of North America

SN - 0039-6109

IS - 3

ER -